Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice
Adenoviral (Ad) vectors represent promising vaccine platforms for infectious disease. To overcome pre-existing immunity to commonly used human adenovirus serotype 5 (Ad5), vectors based on rare species or non-human Ads are being developed. However, these vectors often exhibit reduced potency compare...
Main Authors: | Carly M. Bliss, Andrea J. Parsons, Raffael Nachbagauer, Jennifer R. Hamilton, Federica Cappuccini, Marta Ulaszewska, Jason P. Webber, Aled Clayton, Adrian V.S. Hill, Lynda Coughlan |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-03-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050119301494 |
Similar Items
-
Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines
by: Lynda Coughlan
Published: (2020-05-01) -
Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses
by: Lucas J. Kerstetter, et al.
Published: (2021-01-01) -
Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors
by: Florian Kreppel, et al.
Published: (2021-02-01) -
Analysis of adenoviral attachment to human platelets
by: Urieli-Shoval Simcha, et al.
Published: (2009-02-01) -
Directed evolution in human cells via adenoviral replication
by: Berman, Chet Michael.
Published: (2019)